Document is current
Any future updates will be listed below
-
Authors
Sher-Censor, Efrat https://orcid.org/0000-0003-2961-3129
Harel, Moria
Oppenheim, David https://orcid.org/0000-0001-7019-2106
Aran, Adi https://orcid.org/0000-0001-9460-4689
- License Information
-
More Information
Article History
Accepted: 28 October 2024
First Online: 13 November 2024
Declarations
:
: Adi Aran reports receiving consultation fees and stock options for advisory roles at BOL Pharma (2017–2019), stock options for advisory roles at GCANRx (once, 2021), and consultation fees for advisory roles at Bazelet group (2024-ongoing). These funders had no role in the design of the study; in the collection, analyses, or interpretation of the data; in the writing of the manuscript; or in the decision to publish the results. The remaining authors declare no conflict of interest.
: The study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review Board Shaare Zedek Medical center (#0175-16) and the Israeli Ministry of Health (#20162153).
: Parents provided written informed consent. Written assent was obtained from the children when appropriate.
